Effect of Interferon α-2b on Multicellular Tumor Spheroids of MCF-7 Cell Line Enriched with Cancer Stem Cells





Multicellular tumor spheroids, Cancer stem cells, Interferon alpha, MCF-7


Background. The main problem of cancer treatment is that the disease prediction depends on subpopulations of the primary tumor and the ability of the tumor to recover and form metastases. Cancer stem cells (CSCs) provide self-renewal of the tumor after irradiation and chemotherapy. One way to isolate these cells is to form multicellular tumor spheroids. The method of enrichment of such spheroids by CSCs can be used to test complex antitumor therapy aimed at the CSCs population in vitro. Some studies have shown a close relationship between CSCs and interferon in tumor proliferation and progression. Therefore, it is important to assess the sensitivity of the CSCs population to the action of interferon on a model of multicellular tumor spheroids.

Objective. The aim of the article is to study the sensitivity of MCF-7 cell populations to the effect of IFNα-2b on a model of multicellular tumor spheroids enriched with CSCs.

Methods. To enrich multicellular spheroids with CSCs, adherent cells of monolayer culture MCF-7 (human breast adenocarcinoma) were trypsinized and cultured on an orbital shaker under serum-free conditions with the addition of growth factors (fibroblast growth factor, epidermal growth factor, insulin, and hydrocortisone). In order to study the direct effect of IFNα-2b on cell populations, this cytokine was added to plates with cell aggregates at a concentration of 102 U/mL and 104 U/mL and incubated for 48 h. Counting the number of cells was performed using the routine method with a trypan blue and hemocytometer. Morphometric analysis was performed by measuring the volumes of spheroids using the software Stemi2000 (Zeiss, Germany) and the Bjerkvig formula. Receptor expression was analyzed after two days of incubation using primary monoclonal antibodies CD24 (Sigma, USA), CD44 (Sigma, USA), CD133 (Sigma, USA), bmi-1 (Sigma, USA). For statistical data processing, one-factor analysis of the variance and t-Student testing with the Statistica 8 software package were used. The differences were considered significant at p < 0.05. For each result obtained, we determined the indices of the arithmetic mean (M) and the standard deviation of the arithmetic mean (m).

Results. The presence of CSCs expressing the receptors characteristic of mammary gland (CD24, CD44, CD133, bmi-1) in the culture of multicellular tumor spheroids, which were cultured under serum-free conditions with the addition of growth factors, was shown using immunohistochemistry method. Since cells are obtained from monoculture of tumor cells, it can be assumed that CSCs are detected by appropriate markers, but not stromal cells, for which expression of these receptors is also possible. The data on the effect of IFNα-2b on the heterogeneous population of tumor and stem-like cells were obtained. It turned out that this cytokine effects the reduction of the average volume of cell aggregates by 16% and 25% at a concentration of 102 and 104 U/mL, respectively. It also suppresses cell proliferation by 13% at a concentration of IFNα-2b 104 U/mL, compared with control samples. Further incubation of spheroids with IFNα-2b leads to a decrease in the average and median volumes of spheroids by 48% and 74% at a cytokine concentration of 104 U/mL and 104 U/mL, respectively, compared to control samples. IFNα-2b dose-dependently contributes to the disintegration of multicellular tumor spheroids enriched with CSCs and to the formation of a large number of small cell aggregates and individual cells of the MCF-7 cell line.

Conclusions. IFNα-2b can be considered as an auxiliary agent for the development and testing of complex antitumor therapy aimed at activating СSCs with simultaneous effects of chemotherapy on models of multicellular tumor spheroids of the MCF-7 line, enriched with this cells in vitro.


Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121(10):3810-8. DOI: 10.1172/JCI57088

Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313-9. DOI: 10.1038/nm.2304

Liu S, Dontu G, Wisha M. Mammary stem cells, self-renewal pathways and carcinogenesis. Breast Cancer Res. 2005;7(3):86-95. DOI: 10.1186/bcr1021

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111-5. DOI: 10.1038/nature05384

Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K. Tumor derived spheroids: relevance to cancer stem cells and clinical applications. Cancer Sci. 2017;108(3):283-9. DOI: 10.1111/cas.13155

Prud'homme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des. 2012;18(19):2838-49. DOI: 10.2174/138161212800626120

Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, et al. Sphere-forming cell subpopulation with cancer stem cell properties in human hepatoma cell line. Gastroenterology. 2011;11:71. DOI: 10.1186/1471-230X-11-71

Yilmazer A. Evaluation of cancer stemness in breast cancer and glioblastoma spheroids in vitro. 3 Biotech. 2018;8(9):390. DOI: 10.1007/s13205-018-1412-y

Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311-20. DOI: 10.1158/0008-5472.CAN-08-0364

Tang C, Ang B, Pervaiz S. Cancer stem cell: target for anticancer therapy. FASEBJ. 2007;21(14):3777-85. DOI: 10.1096/fj.07-8560rev

Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8(5):486-98. DOI: 10.1016/j.stem.2011.04.007

Weiswald LB, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia. 2015;17(1):1-15. DOI: 10.1016/j.neo.2014.12.004

Breslin S, O'Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today. 2013;18(5-6):240-8. DOI: 10.1016/j.drudis.2012.10.003

Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759-71. DOI: 10.1038/nrc3611

Morak MJ, van Koetsveld PM, Kanaar R, Hofland LJ, van Eijck CH. Type I interferons as radiosensitisers for pancreatic cancer. Eur J Cancer. 2011;47(13):1938-45. DOI: 10.1016/j.ejca.2011.03.009

Ningrum RA. Interferon alpha 2b: a therapeutic protein for cancer treatment. Scientifica. 2014;1:1-8. DOI: 10.1155/2014/970315

Zhu Y, Karakhanova S, Huang X, Deng SP, Werner J, Bazhin AV. Influence of interferon α on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp Cell Res 2014;324(2):146-56. DOI: 10.1016/j.yexcr.2014.03.020

Yamashina T, Baghdadi M, Yoneda A, Kinoshita I, Suzu S, Dosakaakita H, et al. Cancer stem like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells. Cancer Res. 2014;74(10):2698-709. DOI: 10.1158/0008-5472.CAN-13-2169

Portillo-Lara R, Alvarez MM. Enrichment of the cancer stem phenotype in sphere cultures of prostate cancer cell lines occurs through activation of developmental pathways mediated by the transcriptional regulator ΔNp63α. PLoS ONE. 2015;10(6):e0130118. DOI: 10.1371/journal.pone.0130118

Bjerkvig R. Spheroid culture in cancer research. Boca Raton: CRC Press; 1992. 335 p.

Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells – a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol. 2005;16(4-5):554-63. DOI: 10.1016/j.semcdb.2005.03.007

Wang Z, Wang Q, Wang Q, Wang Y, Chen J. Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis. Int J Biol Markers. 2017;32(1):75-82. DOI: 10.5301/jbm.5000224

Wu J, Mu Q, Thiviyanathan V, Annapragada A, Vigneswaran N. Cancer stem cells are enriched in Fanconi anemia head and neck squamous cell carcinomas. Int J Oncol. 2014;45(6):2365-72. DOI: 10.3892/ijo.2014.2677

Kemlin LC, Casagrande G, Virador VM. In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog. 2013;52(3):167-82. DOI: 10.1002/mc.21844

Chen SC, Soares HD, Morgan JI. Novel molecular correlates of neuronal death and regeneration. Adv Neurol. 1996;71:433-49.

Ma H, Jin S, Yang W, Tian Z, Liu S, Wang Y, et al. Interferon-α promotes the expression of cancer stem cell markers in oral squamous cell carcinoma. J Cancer. 2017;8(12):2384-93. DOI: 10.7150/jca.19486

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946-51. DOI: 10.1158/0008-5472.CAN-05-2018

Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-14. DOI: 10.1038/sj.cdd.4402283

Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9(1):50-63. DOI: 10.1016/j.stem.2011.06.005

Huang Z, Wu T, Liu AY, Ouyang G. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget. 2015;6:39550-63. DOI: 10.18632/oncotarget.6098

Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell. 2007;1(6):607-11. DOI: 10.1016/j.stem.2007.11.009

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, et al. CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol. 2012;43(3):364-73. DOI: 10.1016/j.humpath.2011.05.005

Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J. 2015;36(3):273-9. DOI: 10.15537/smj.2015.3.9622

Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck. 2012;34(1):42-9. DOI: 10.1002/hed.21699

Handgretinger R, Gordon PR, Leimig T, Chen X, Buhring HJ, Niethammer D, et al. Biology and plasticity of CD133+ hematopoietic stem cells. Ann N Y Acad Sci. 2003;996(1):141-51. DOI: 10.1111/j.1749-6632.2003.tb03242.x

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-8.

Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol. 2013;2(1):17-8. DOI: 10.1186/2162-3619-2-17

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401. DOI: 10.1038/nature03128

Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 2003;425(6961):962-7. DOI: 10.1038/nature02060

Nör C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014;16(2):137-46. DOI: 10.1593/neo.131744

Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063-71. DOI: 10.1158/0008-5472.CAN-06-0054

Wang Y, Zhe H, Ding Z, Gao P, Zhang N, Li G. Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg. 2012;36(5):1189-94. DOI: 10.1007/s00268-012-1514-3

Wang MC, Li CL, Cui J, Jiao M, Wu T, Jing LI, et al. BMI-1, a promising therapeutic target for human cancer. Oncology Letters. 2015;10(2):583-8. DOI: 10.3892/ol.2015.3361

Keith B, Simon MC. Hypoxia Inducible Factors, stem cells and cancer. Cell. 2007;129(3):465-72. DOI: 10.1016/j.cell.2007.04.019

Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405-14. DOI: 10.1038/nri3845

Iacopino F, Ferrandina G, Scambia G, Benedetti-Panici P, Mancuso S, Sica G. Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells. Anticancer Res. 1996;16:1919-24.

Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131-44. DOI: 10.1038/nrc.2016.14

Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10:201-9. DOI: 10.1038/nri2726



How to Cite

Herheliuk T, Perepelytsina O, Ostapchenko L, Sydorenko M. Effect of Interferon α-2b on Multicellular Tumor Spheroids of MCF-7 Cell Line Enriched with Cancer Stem Cells. Innov Biosyst Bioeng [Internet]. 2019Mar.22 [cited 2023May30];3(1):34-4. Available from: http://ibb.kpi.ua/article/view/157388